Core Mechanism PROVEN
α-Synuclein — Cortical + Limbic Distribution
Same protein as Parkinson's (PD) but different anatomical distribution. LBD = cortex + limbic system predominant. PD = brainstem (substantia nigra) predominant. Both are synucleinopathies. Cortical Lewy bodies = dementia. Brainstem Lewy bodies = motor symptoms.
Spillantini 1997 Nature (α-synuclein in Lewy bodies) · McKeith 2017 Neurology (4th DLB consensus)
DLB-1yr Rule
Dementia within 1yr of parkinsonism onset = DLB (Dementia with Lewy Bodies). Parkinsonism >1yr before dementia = PD Dementia (PDD). Arbitrary but clinically used. Same pathology, different labelling by timing.
McKeith et al. 2017 Neurology — 4th consensus criteria
REM Sleep Behavior Disorder (RBD) — Prodromal
Dream enactment: punching, kicking, vocalising during REM sleep. Brainstem nuclei that normally suppress movement during REM fail. RBD is prodromal in ~80% of DLB/PD cases. Appears years before dementia. Postuma: ~80% RBD → synucleinopathy over 14yr.
Postuma et al. 2019 Lancet Neurol (RBD as prodromal synucleinopathy)
Fluctuating Cognition — Pathognomonic
Minutes-to-hours variation in alertness and cognition. Not day-to-day variation (that's normal). Sudden episodes of confusion then clarity. Mechanism: thalamic-cortical circuit instability from Lewy body involvement of thalamus. Distinguishes DLB from AD.
McKeith 2017 — Core diagnostic feature
Visual Hallucinations (60–80%)
Well-formed, detailed, often non-threatening hallucinations (people, animals). Distinct from schizophrenia (less frightening). Mechanism: posterior cortical Lewy bodies disrupting visual association areas + cholinergic deficit.
McKeith 2017 — Core diagnostic feature
Dual Deficit
Dopaminergic deficit: Substantia nigra Lewy bodies → parkinsonism (70% of DLB). Responds partially to L-DOPA.
Cholinergic deficit: Nucleus basalis of Meynert more severely depleted than in AD. Worse than AD. Explains visual hallucinations and cognitive fluctuations. Also explains why ChEIs work well in DLB.
Cholinesterase Inhibitors PROVEN
Rivastigmine — PROVEN for DLB
EXPRESS trial: rivastigmine improved cognition AND reduced hallucinations in DLB. Cholinergic deficit more severe than AD → larger effect size. First-line pharmacotherapy for DLB. Both oral and patch formulations used.
McKeith et al. 2000 Lancet (EXPRESS trial) · Lancet Neurol 2004
CRITICAL CONTRAINDICATION LIFE-THREATENING
⚠ NO ANTIPSYCHOTICS — Neuroleptic Sensitivity
50% of DLB patients develop severe, potentially fatal reactions to typical AND atypical antipsychotics. Neuroleptic malignant syndrome-like reaction: rigidity, impaired consciousness, autonomic instability. Even "atypical" antipsychotics (quetiapine, olanzapine) dangerous. MECHANISM UNCLEAR — SORRY.
McKeith et al. 1992 (neuroleptic sensitivity) · 50% severe reaction rate · can be fatal
Parkinsonism Management
L-DOPA — Limited Benefit
Lower doses than idiopathic PD. Partial motor benefit. Can worsen hallucinations. Used cautiously when parkinsonism is disabling. Balance: motor gain vs hallucination worsening.
Walker et al. 2015 (DLB motor management)
Clonazepam for RBD
Low-dose clonazepam at bedtime. Reduces dream enactment. Does not prevent synucleinopathy conversion. Melatonin (3–12mg) used as alternative with fewer side effects.
Aurora et al. 2010 (RBD treatment guidelines)
No Disease-Modifying Treatment SORRY
No approved α-synuclein targeting therapy. Prasinezumab (anti-α-syn mAb) and other approaches in Phase 2. SORRY: the same target failure as PD. Aggregation inhibition, clearance enhancement — all in trials.
SORRY: no DMT approved for LBD as of 2026
Diagnostic Biomarkers
| DAT-SPECT PROVEN | DaTSCAN (ioflupane I-123). Reduced striatal dopamine transporter = dopaminergic deficit. Distinguishes LBD from AD (which has normal DAT). FDA approved. High sensitivity ~78%, specificity ~90%. McKeith 2017 |
| PSG — RBD confirmation | Polysomnography. REM without atonia = RBD. Gold standard for RBD diagnosis. Can be done before dementia for prodromal identification. |
| MIBG cardiac | 123I-MIBG scintigraphy. Cardiac sympathetic denervation in LBD/PD. Reduced heart-to-mediastinum ratio. Distinguishes from AD. Supportive biomarker in McKeith 2017. |
| α-syn RT-QuIC | Real-time quaking-induced conversion. CSF seeding assay. 93% sensitivity for α-synucleinopathy. Not yet standardised. Emerging diagnostic tool. Fairfoul et al. 2016 |
Open Sorries
SORRY-1: DLB 1-year rule is arbitrary — same pathology regardless of timing. Creates artificial diagnostic boundary.
SORRY-2: Neuroleptic sensitivity mechanism is unknown. Cannot predict which patients will have severe reactions.
SORRY-3: RBD → LBD conversion rate is ~80% over 14yr but timing is completely unpredictable.
SORRY-4: No disease-modifying treatment despite clear target (α-synuclein).
EEG Signatures — DLB
| Posterior slow ↑ | Slowing of posterior dominant rhythm. Earlier and more prominent than AD. Reflects posterior cortical involvement by Lewy bodies. |
| Theta excess | Diffuse theta increase. Correlates with cognitive fluctuation severity. |
| TSA STRONG | Transient Slow-wave Activity — pathognomonic for DLB. Intermittent, well-defined slow waves in posterior regions during wakefulness. Reflects thalamocortical circuit instability. Bonanni et al. 2008 Neurology |
| Alpha power ↓ | Posterior alpha reduction. More severe than AD at equivalent cognitive stage. Posterior cortex heavily affected by Lewy bodies. |
TSA Clinical Utility
Transient Slow-wave Activity (TSA) during wakefulness EEG is the most distinctive DLB EEG feature. Bonanni et al. 2008: TSA sensitivity 64%, specificity 92% vs AD. Correlates with fluctuation severity. Can be captured during routine EEG — not sleep-dependent. The fluctuating cognition shows up directly in the EEG trace.
Novel Patterns (8)
PROVENNP-LBD-001 · DLB-1yr rule: same α-syn pathology, different label based on arbitrary timing — clinical convenience not biology
PROVENNP-LBD-002 · RBD: 80% conversion to synucleinopathy over 14yr — the clearest prodromal biomarker in any neurodegenerative disease
PROVENNP-LBD-003 · Cholinergic deficit WORSE than AD in DLB — explains why rivastigmine works AND why hallucinations are a hallmark
PROVENNP-LBD-004 · Neuroleptic sensitivity = potentially fatal in 50% · ALL antipsychotics contraindicated · mechanism unknown
PROVENNP-LBD-005 · DAT-SPECT distinguishes LBD from AD — reduced dopamine transporter even before motor symptoms
OPENNP-LBD-006 · TSA (transient slow-wave activity) on waking EEG — pathognomonic for DLB, correlates with fluctuation severity
OPENNP-LBD-007 · α-syn RT-QuIC CSF assay: 93% sensitivity for synucleinopathy — not yet standardised but game-changing if validated
SORRYNP-LBD-008 · No DMT · neuroleptic sensitivity mechanism unknown · RBD→LBD timing unpredictable · 1-yr rule arbitrary · same α-syn as PD, same treatment gap